TNT: Triple Negative breast cancer Trial

Collection of samples and data across the following diseases: Malignant tumour of breast TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 weeks) Group B: Docetaxel 100mg/m2, q 3 weeks for 6 cycles (18 weeks) On evidence of disease progression, patients will cross over to the alternative treatment.

Webpage:
https://www.healthdatagateway.org/dataset/56f3e791-a204-4f67-a4d0-52803148d71a

Licence:
Name: HDR UK Innovation Gateway Access
URL: https://www.hdruk.ac.uk/infrastructure/gateway/terms-and-conditions/

Tags:

breast cancer trial malignant tumour of breast triple negative tnt

More to explore:

1/20

Previous Next   



Need help integrating and/or managing biomedical data?